MRK Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Merck & Co Inc (MRK) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company has some positive catalysts, such as FDA approval for its vaccine and a recent drug discovery deal, the technical indicators, insider selling, and lack of strong trading signals suggest waiting for a better entry point. The stock's current price trend and neutral analyst sentiment do not provide a compelling case for immediate investment.
The MACD histogram is negative and expanding, indicating bearish momentum. RSI is neutral at 30.228, and moving averages are converging, showing no clear trend. The stock is trading near its support level of 113.074, with resistance at 117.616.
FDA approval for the pneumococcal vaccine Capvaxive for children aged 2 to
A $510 million drug discovery deal with Protillion Biosciences to enhance drug development capabilities.
Insider selling has increased by 2945.40% over the last month.
Neutral hedge fund sentiment with no significant trading trends.
Analysts are cautious, with some maintaining neutral or equal-weight ratings.
No financial data available for the latest quarter.
Analysts have mixed views. Citi reinstated coverage with a Neutral rating and a $125 price target. Morgan Stanley raised the price target to $112 but maintained an Equal Weight rating. UBS and JPMorgan are more optimistic, with price targets of $145 and $135, respectively, citing pipeline execution and favorable risk/return.
